Comparison of antiviral effect of lamivudine with interferon-α2a versus -α2b in children with chronic hepatitis B infection

Antiviral Therapy

Volumn 9, Issue 1, 2004, Pages 23-26

  Ozgenc, Funda ^a   Dikici, Bunyamin ^b   Targan, Seref ^c   Doganci, Tumay ^d   Akman, Sezin ^a   Aydogdu, Sema ^a   Yagci, Rasit Vural ^a  

^a EGE UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

^c DR BEHÇET UZ CHILDREN'S HOSPITAL   (Turkey)

^d Diskapi SSK Children's Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CHILDHOOD DISEASE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LIVER BIOPSY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; THROMBOCYTOPENIA; VIRUS DIAGNOSIS;

ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LAMIVUDINE; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 1542319033     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ertekin V, Selimoglu MA & Altinkaynak S. Sero-epidemiology of hepatitis B infection in an urban paediatric population in Turkey. Public Health 2003; 117(1):49-53.
2. Bortolotti F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F, Calzia R & Realdi G. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990; 99:805-810.
3. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri S, Annese M, Matarazzo F, Di Stefano G & Barbarini G; Lamivudine Italian Study Group Investigators. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology 2001; 35(3):406-411.
4. Mutimer D, Dowling D, Cane P, Ratcliffe D, Tang H, O'Donnell K, Shaw J, Elias E & Pillay D. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antiviral Therapy 2000; 5(4):273-277.
5. Dikici B, Bosnak M, Bosnak V, Dagli A, Davutoglu M, Yagci RV & Haspolat K. Comparision of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatrics International 2002; 44(5):517-521.
6. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. Journal of Gastroenterology & Hepatology 2002; 17(4):409-414.
7. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri S, Annese M, Matarazzo F, Di Stefano G & Barbarini G; Lamivudine Italian Study Group Investigators. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology 2001; 35(3):406-411.
8. Selimoglu MA, Aydogdu S, Unal F, Zeytinoglu A, Yuce G & Yagci RV. Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatrics International 2002; 44(4):404-408.
9. Fish E, Banerjee K & Stebbing N. Human leucocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochemical & Biophysical Research Communications 1983; 112:537-546.
10. Weck P, Appeson S, May L & Stebbing N. Comparision of the antiviral activities of various cloned human interferon alpha subtypes in mammalian cell cultures. Journal of General Virology 1981; 57:233-242.
11. Foster GR & Finter NB. Are all type I human interferons equivalent? Journal of Viral Hepatitis 1998; 5:143-152.
12. Zoulim F. Detection of hepatitis B virus resistance to antivirals. Journal of Clinical Virology 2001; 21(3):243-253.
13. Dikici B, Bosnak M, Kara IH, Dogru O, Dagli A, Gurkan F & Haspolat K. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatric Infectious Disease Journal 2001; 20(10):988-992.
14. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hatturn J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P & Schalm SW. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral hepatitis (EUROHEP). Hepatology 1999; 30(1):238-243.
15. Simon K, Retter K & Zalewska M. HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis B. Medical Science Monitor 2000; 6(5):971-975.
16. Gurakan F, Kocak N, Ozen H & Yuce A. Comparision of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatric Infectious Disease Journal 2000; 19(1):52-56.
17. Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, Dastoli G, Pastore G, Ideo G, Bonino F & Brunetto MR. Long term response to therapy of chronic anti-HBe positive hepatitis B is poor independent of type and schedule of interferon. American Journal of Gastroenterology 1999; 94(5):1366-1372.
18. Papatheodoridis GV, Dimou E & Papadimitropoulus V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. American Journal of Gastroenterology 2002; 97(7):1618-1628.